Related Experiment Video

Updated: Jan 21, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer

Jennifer Weiss1, Ashley Glode2, Wells A Messersmith3

  • 1School of Medicine, University of Colorado Anschutz Medical Campus , Aurora , CO , USA.

Expert Review of Anticancer Therapy
|August 10, 2019
PubMed

Insights

Sacituzumab govitecan shows promise for treating metastatic triple-negative breast cancer (TNBC) after other therapies fail. This antibody-drug conjugate has a manageable side effect profile and potential in other epithelial cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Medicine

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies, making chemotherapy the primary treatment.
  • Limited treatment options for TNBC contribute to high recurrence and mortality rates.
  • Sacituzumab govitecan offers a novel targeted approach for TNBC management.

Purpose of the Study:

  • To review the mechanism of action, safety, and efficacy of sacituzumab govitecan in pre-treated metastatic TNBC.
  • To explore the potential of sacituzumab govitecan in other epithelial malignancies.
  • To provide expert opinion on the clinical utility of sacituzumab govitecan.

Main Methods:

  • Literature review of sacituzumab govitecan, focusing on clinical trial data.
  • PubMed search for 'sacituzumab govitecan' and 'clinical trial' to identify relevant studies.
  • Analysis of efficacy and safety data from Phase I/II and ongoing Phase III trials.

Main Results:

  • Sacituzumab govitecan demonstrated promising anti-cancer activity in a Phase I/II trial for metastatic TNBC.
  • The drug exhibits a manageable side effect profile, with common adverse events including nausea, neutropenia, and diarrhea.
  • Early data suggests potential efficacy in other epithelial cancers, including hormone receptor-positive breast cancer.

Conclusions:

  • Sacituzumab govitecan represents a promising therapeutic option for patients with previously treated metastatic TNBC.
  • Ongoing Phase III trials are crucial for confirming its efficacy in TNBC.
  • The drug's activity may extend to other epithelial malignancies, warranting further investigation.
Keywords:
IMMU-132Sacituzumab govitecanTrop-2antibody-drug conjugatemetastatic breast cancertriple-negative breast cancer (TNBC)

More Related Videos

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.5K
Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography10:10

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography

Published on: July 29, 2011

15.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Scalar and Vector Triple Products01:06

Scalar and Vector Triple Products

Two vectors can be multiplied using a scalar product or a vector product. The resultant of a scalar product is scalar, while with vector products, the resultant is a vector. These rules of the scalar or vector product between two vectors can be applied to multiple vectors to obtain meaningful combinations. The scalar triple product is the dot product of a vector with the cross product of two vectors.
The scalar triple product is the dot product of a vector with the cross product of two vectors....
4.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.3K
Positive, Negative, and Zero Work00:58

Positive, Negative, and Zero Work

Work is done on an object when energy is transferred to the object. In other words, work is done when a force acts on a body that undergoes a displacement from one position to another. By definition, the work done by a force is the integral of the force with respect to the displacement along its path. Forces can vary as a function of position, and displacements can occur along various paths between two points. The magnitude of a force multiplied by the cosine of the angle that the force makes...
22.0K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K